Brokerages forecast that Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) will post ($0.52) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Spring Bank Pharmaceuticals’ earnings. Spring Bank Pharmaceuticals reported earnings of ($0.47) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 10.6%. The business is expected to report its next quarterly earnings report on Friday, April 27th.
On average, analysts expect that Spring Bank Pharmaceuticals will report full year earnings of ($2.41) per share for the current fiscal year, with EPS estimates ranging from ($3.09) to ($2.11). For the next year, analysts anticipate that the firm will post earnings of ($2.51) per share, with EPS estimates ranging from ($3.09) to ($1.96). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Spring Bank Pharmaceuticals.
Spring Bank Pharmaceuticals (NASDAQ:SBPH) last posted its quarterly earnings results on Tuesday, February 20th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.18.
SBPH traded down $0.75 on Tuesday, hitting $13.50. 27,491 shares of the company were exchanged, compared to its average volume of 33,616. Spring Bank Pharmaceuticals has a 12 month low of $7.95 and a 12 month high of $18.93. The firm has a market cap of $175.01, a price-to-earnings ratio of -7.22 and a beta of -0.35.
Several hedge funds have recently modified their holdings of the company. BVF Inc. IL grew its position in shares of Spring Bank Pharmaceuticals by 26.2% in the 4th quarter. BVF Inc. IL now owns 823,474 shares of the company’s stock worth $11,076,000 after buying an additional 170,798 shares during the last quarter. AXA grew its position in shares of Spring Bank Pharmaceuticals by 7.6% in the 4th quarter. AXA now owns 266,585 shares of the company’s stock worth $3,583,000 after buying an additional 18,859 shares during the last quarter. Morse Asset Management Inc grew its position in shares of Spring Bank Pharmaceuticals by 18.4% in the 4th quarter. Morse Asset Management Inc now owns 146,875 shares of the company’s stock worth $1,821,000 after buying an additional 22,875 shares during the last quarter. Sectoral Asset Management Inc grew its position in shares of Spring Bank Pharmaceuticals by 9.7% in the 3rd quarter. Sectoral Asset Management Inc now owns 123,383 shares of the company’s stock worth $2,078,000 after buying an additional 10,883 shares during the last quarter. Finally, Vanguard Group Inc. bought a new stake in shares of Spring Bank Pharmaceuticals in the 2nd quarter worth approximately $794,000. Hedge funds and other institutional investors own 28.65% of the company’s stock.
Spring Bank Pharmaceuticals Company Profile
Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.